Australia markets closed

Amarin Corporation plc (AMRN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.99+0.27 (+4.72%)
At close: 4:00PM EST

5.98 -0.01 (-0.17%)
After hours: 5:59PM EST

Amarin Corporation plc

Grand Canal Docklands
Block C 77 Sir John Rogerson's Quay
Dublin 2
Ireland
353 1 669 9020
http://www.amarincorp.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees1,000

Key executives

NameTitlePayExercisedYear born
Mr. John F. TheroPres, CEO & Director1.34M2.79M1961
Mr. Michael W. KalbCFO, Sr. VP & Assistant Sec.672.6k6.74M1971
Dr. Steven B. KetchumPres of R&D, Sr. VP and Chief Scientific Officer837.7k1.55M1965
Mr. Joseph T. KennedyExec. VP, Gen. Counsel & Strategic Initiatives and Sec.797.7k12.4M1968
Mr. Aaron D. BergSr. VP & Chief Commercial Officer673.59k5.43M1963
Ms. Elisabeth SchwartzSr. Director of Investor RelationsN/AN/AN/A
Mr. Daniel S. DunhamSr. VP & Chief Pharmaceutical Compliance OfficerN/AN/AN/A
Alina KolomeyerDirector of CommunicationsN/AN/AN/A
Mr. Rami DaoudSr. VP of Corp. Devel.N/AN/AN/A
Ms. Donna PasekSr. VP of HRN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Amarin Corporation plc, a pharmaceutical company, develops and commercializes therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing REDUCE-IT for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Corporate governance

Amarin Corporation plc’s ISS governance QualityScore as of 3 December 2020 is 8. The pillar scores are Audit: 7; Board: 8; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.